نتائج البحث

FDA Refuses NDA for Cutaneous T-Cell Lymphoma.

Subjects: DRUG approval; PHOTODYNAMIC therapy; HYPERICUM perforatum

• Source: Formulary Watch. 2/14/2023, p1-1. 1p.

تفاصيل العنوان

Soligenix Submits NDA for Novel Therapy for Cutaneous T-cell Lymphoma.

Subjects: THERAPEUTIC use of antineoplastic agents; DRUG approval; INVESTIGATIONAL drugs

• Source: Formulary Watch. 12/15/2022, p1-1. 1p.

تفاصيل العنوان

LYMPHOMA: (HODGKIN, NHL, DLBCL, FOLLICULAR, MANTLE-CELL, MARGINAL-ZONE, SLL).

• Source: Conquer. 2021Special issue, p108-131. 24p.

تفاصيل العنوان

FDA Accepts BLA for Cutaneous T-Cell Lymphoma Therapy.

Subjects: THERAPEUTIC use of antineoplastic agents; DRUG approval; UNITED States. Food & Drug Administration

• Source: Formulary Watch. 12/2/2022, p2-2. 1p.

تفاصيل العنوان

LYMPHOMA.

• Source: Conquer. 2020Special issue, p103-122. 20p.

تفاصيل العنوان

FDA Sets Action Date for Resubmitted Lymphir in Rare Skin Cancer.

Subjects: SKIN tumors; RARE diseases; FATIGUE (Physiology)

• Source: Formulary Watch. 3/18/2024, p1-2. 2p.

تفاصيل العنوان

DRUGS for LYMPHOMA.

• Source: Conquer. 2019Special issue, p92-109. 18p.

تفاصيل العنوان

LYMPHOMA.

• Source: Conquer. 2018 Special issue, p83-97. 15p.

تفاصيل العنوان

Celgene Patient Support Services.

• Source: Oncology Practice Management. 2019Special Feature, p34-36. 3p.

تفاصيل العنوان

FDA Rejects BLA for Therapy to Treat Rare Skin Cancer.

Subjects: DRUG efficacy; BIOLOGICAL products; INTERLEUKIN-2

• Source: Formulary Watch. 7/31/2023, p1-1. 1p. 1 Color Photograph.

تفاصيل العنوان